Further research and reporting of such cases are crucial to better understand the full spectrum of adverse effects associated with risankizumab and similar IL-23 inhibitors [6,7]. IL-23 is a pro-inflammatory cytokine that plays a central role in the activation and differentiation of T-helper 17 (Th17) cells, which are crucial in the pathogenesis of various autoimmune diseases. The gene discussed is IL37; the disease is autoimmune disease.